Moreover, a clinical trial of CEA CAR-T therapy on patients with carcino-embryonic antigen (CEA)-positive colorectal cancer (CRC) carried out by Zhang et al. showed that the third generation of CAR with CD28 and CD137 signaling does not show better performance than the second generation with CD28 signaling [33]. This evidence concerns the gene CD28 and colorectal carcinoma.